Aromatase inhibitors for breast cancer prevention

Journal of Clinical Oncology

Volumn 23, Issue 8, 2005, Pages 1636-1643

  Cuzick, Jack ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; EXEMESTANE; FADROZOLE; FORMESTANE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LETROZOLE; MEGESTROL ACETATE; PLACEBO; RISEDRONIC ACID; TAMOXIFEN; VITAMIN D DERIVATIVE; VOROZOLE; ANTINEOPLASTIC AGENT; ESTRADIOL;

ARTHRALGIA; ARTHRITIS; BREAST CANCER; CANCER PREVENTION; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CATARACT; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DEPRESSION; DIARRHEA; DIZZINESS; DRUG MONITORING; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; EDEMA; ENDOMETRIUM CANCER; FATIGUE; FRACTURE; GYNECOLOGIC DISEASE; HEADACHE; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; INSOMNIA; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; MASTECTOMY; MOOD DISORDER; MUSCLE CRAMP; MUSCULOSKELETAL DISEASE; MYALGIA; NAUSEA; NAUSEA AND VOMITING; OSTEOPOROSIS; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SAMPLE SIZE; SIDE EFFECT; SWEATING; THROMBOEMBOLISM; UNSPECIFIED SIDE EFFECT; VAGINA BLEEDING; VAGINA DISCHARGE; VENOUS THROMBOEMBOLISM; VISUAL FIELD DEFECT; ADJUVANT CHEMOTHERAPY; BLOOD; BREAST TUMOR; CASE CONTROL STUDY; ESTROGEN THERAPY; FEMALE; POSTMENOPAUSE;

ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CHEMOTHERAPY, ADJUVANT; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; POSTMENOPAUSE; TAMOXIFEN;

EID: 15544390511     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.11.027     Document Type: Review

References (31)

1. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 350:1047-1059, 1997
2. Beral V: Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362:419-427, 2003
3. Rossouw JE, Anderson GL, Prentice RL, et al: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321-333, 2002
4. Chlebowski RT, Hendrix SL, Langer RD, et al: Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: The Women's Health Initiative Randomized Trial. JAMA 289:3243-3253, 2003
5. Key T, Appleby P, Barnes I, et al: Endogenous sex hormones and breast cancer in postmenopausal women: Reanalysis of nine prospective studies. J Natl Cancer Inst 94:606-616, 2002
6. Cuzick J, Powles T, Veronesi U, et al: Overview of the main outcomes in breast-cancer prevention trials. Lancet 361:296-300, 2003
7. Dombernowsky P, Smith I, Falkson G, et al: Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 16:453-461, 1998
8. Kaufmann M, Bajetta E, Dirix LY, et al: Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol 18:1399-1411, 2000
9. Buzdar AU, Jonat W, Howell A, et al: Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: Results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer 83:1142-1152, 1998
10. Goss PE, Winer EP, Tannock IF, et al: Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. North American Vorozole Study Group. J Clin Oncol 17:52-63, 1999
11. Buzdar AU, Smith R, Vogel C, et al: Fadrozole HCL (CGS-16949A1 versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: Results of two randomized double blind controlled multi-institutional trials. Cancer 77:2503-2513, 1996
12. Thurlimann B, Castiglione M, Hsu-Schmitz SF, et al: Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: A phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Swiss Group for Clinical Cancer Research (SAKK). Eur J Cancer 33:1017-1024, 1997
13. Bonneterre J, Buzdar A, Nabholtz JM, et al: Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 92:2247-2258, 2001
14. Milla-Santos A, Milla L, Portella J, et al: Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: A prospective, randomized, phase III study. Am J Clin Oncol 26:317-322, 2003
15. Falkson CI, Falkson HC: A randomised study of CGS 16949A (fadrozole) versus tamoxifen in previously untreated postmenopausal patients with metastatic breast cancer. Ann Oncol 7:465-469, 1996
16. Thurlimann B, Beretta K, Bacchi M, et al: First-line fadrozole HCl (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88. Ann Oncol 7:471-479, 1996
17. Perez Carrion R, Alberola Candel V, Calabresi F, et al: Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer. Ann Oncol 5:S19-S24, 1994 (suppl 7)
18. Smith IE, Fitzharris BM, McKinna JA, et al: Aminoglutethimide in treatment of metastatic breast carcinoma. Lancet 2:646-649, 1978
19. Lipton A, Harvey HA, Santen RJ, et al: A randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer. Cancer 50:2265-2268, 1982
20. Gale KE, Andersen JW, Tormey DC, et al: Hormonal treatment for metastatic breast cancer. An Eastern Cooperative Oncology Group phase III trial comparing aminoglutethimide to tamoxifen. Cancer 73:354-361, 1994
21. Baum M, Buzdar A, Cuzick J, et al: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 98:1802-1810, 2003
22. Baum M, Buzdar AU, Cuzick J, et al: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 359:2131-2139, 2002
23. Coombes RC, Hall E, Gibson LJ, et al: A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081-1092, 2004
24. Boccardo F, Rubagotti A, Amoroso D, et al: Anastrozole appears to be superior to tamoxifen in women already receiving adjuvant tamoxifen treatment. Breast Cancer Res Treat 82:S6, 2003 (abstr 3)
25. Goss PE, Ingle JN, Martine S, et al: A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793-1802, 2003
26. Howell A, Cuzick J, Baum M, et al: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365:60-62, 2005
27. Jakesz R, Kaufmann M, Gnant M, et al: Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: Combined results from 3,123 women enrolled in the ABCSG Trial 8 and the ARNO 95 Trial. Breast Cancer Res Treat 88:S7, 2004 (abstr 2)
28. Howell A: Effect of anastrozole of bone mineral density: 2-years results of the 'Arimidex' (anastrozole), tamoxifen, alone or in combination (ATAC) trial. Breast Cancer Res Treat 82:S27, 2003 (abstr 129, suppl 1)
29. Goss PE, Qi S, Josse RG, et al: The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats. Bone 34:384-392, 2004
30. Warner E, Lockwood G, Tritchler D, et al: The risk of breast cancer associated with mammographic parenchymal patterns: A meta-analysis of the published literature to examine the effect of method of classification. Cancer Detect Prev 16:67-72, 1992
31. Martino S, Cauley J, Barrett-Connor E, et al: Incidence of invasive breast cancer following 8 years of raloxifene therapy in post-menopausal women with osteoporosis: results from the Continuing Outcomes Relevant to Evista (CORE) trial. Proc Am Soc Clin Oncol 22:14S, 2004 (abstr 1000)